Compare FTFT & CELZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTFT | CELZ |
|---|---|---|
| Founded | N/A | 1998 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9M | 6.4M |
| IPO Year | 2008 | 2008 |
| Metric | FTFT | CELZ |
|---|---|---|
| Price | $3.36 | $0.94 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 12.8M | 240.4K |
| Earning Date | 11-13-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.08 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,829,805.00 | $6,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 77.46 | N/A |
| 52 Week Low | $0.45 | $0.62 |
| 52 Week High | $9.74 | $6.25 |
| Indicator | FTFT | CELZ |
|---|---|---|
| Relative Strength Index (RSI) | 49.62 | 45.69 |
| Support Level | $0.90 | $0.80 |
| Resistance Level | $9.74 | $2.42 |
| Average True Range (ATR) | 1.41 | 0.10 |
| MACD | -0.28 | 0.00 |
| Stochastic Oscillator | 2.62 | 41.91 |
Future FinTech Group Inc is engaged in the production and sale of fruit juice concentrates (including fruit purees and fruit juices), fruit beverages (including fruit juice beverages and fruit cider beverages) in the PRC. The company participates in supply chain financing services and trading in China, asset management business in Hong Kong, and cross-border money transfer services in the United Kingdom. It has also expanded into brokerage and investment banking business in Hong Kong and a cryptocurrency mining farm in the U.S. The Company classified its business segments into Trading Commission and Consulting services, Fast-Moving Consumer Goods (FMCG), and Supply Chain Financing and Trading.
Creative Medical Technology Holdings Inc is a commercial-stage biotechnology company focused on the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. Its pipeline consists of AlloStem (CELZ-201-DDT); ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, an intervention for the treatment of recent onset Type 1 Diabetes; AlloStemSpine for treatment of lower back pain; the Alova program to treat infertility as a result of premature ovarian failure; and other regenerative treatment programs and technologies like OvaStem, CaverStem, FemCelz, StemSpine, and others for the treatment of various indications related to sexual health, spine disc disease, kidney failure, liver failure, etc.